University of Nebraska Medical Center

DigitalCommons@UNMC
Journal Articles: Epidemiology

Epidemiology

2021

The Size and Culturability of Patient-Generated SARS-CoV-2
Aerosol
Joshua L. Santarpia
Vicki L. Herrera
Danielle N. Rivera
Shanna Ratnesar-Shumate
St. Patrick Reid

See next page for additional authors

Follow this and additional works at: https://digitalcommons.unmc.edu/coph_epidem_articles
Part of the Epidemiology Commons

Authors
Joshua L. Santarpia, Vicki L. Herrera, Danielle N. Rivera, Shanna Ratnesar-Shumate, St. Patrick Reid,
Daniel N. Ackerman, Paul W. Denton, Jacob W. S. Martens, Ying Fang, Nicholas Conoan, Michael V.
Callahan, James V. Lawler, David Brett-Major, and John Lowe

Journal of Exposure Science & Environmental Epidemiology

ARTICLE

www.nature.com/jes

OPEN

The size and culturability of patient-generated SARS-CoV-2
aerosol
✉
Joshua L. Santarpia 1,2,3,11 , Vicki L. Herrera1,2, Danielle N. Rivera3, Shanna Ratnesar-Shumate1,2, St. Patrick Reid1,2,11,
3
Daniel N. Ackerman , Paul W. Denton4, Jacob W. S. Martens4, Ying Fang5, Nicholas Conoan6, Michael V. Callahan7, James V. Lawler2,8,
David M. Brett-Major2,9 and John J. Lowe2,10,11
© The Author(s) 2021

BACKGROUND: Aerosol transmission of COVID-19 is the subject of ongoing policy debate. Characterizing aerosol produced by
people with COVID-19 is critical to understanding the role of aerosols in transmission.
OBJECTIVE: We investigated the presence of virus in size-fractioned aerosols from six COVID-19 patients admitted into mixed
acuity wards in April of 2020.
METHODS: Size-fractionated aerosol samples and aerosol size distributions were collected from COVID-19 positive patients. Aerosol
samples were analyzed for viral RNA, positive samples were cultured in Vero E6 cells. Serial RT-PCR of cells indicated samples where
viral replication was likely occurring. Viral presence was also investigated by western blot and transmission electron
microscopy (TEM).
RESULTS: SARS-CoV-2 RNA was detected by rRT-PCR in all samples. Three samples conﬁdently indicated the presence of viral
replication, all of which were from collected sub-micron aerosol. Western blot indicated the presence of viral proteins in all but one
of these samples, and intact virions were observed by TEM in one sample.
SIGNIFICANCE: Observations of viral replication in the culture of submicron aerosol samples provides additional evidence that
airborne transmission of COVID-19 is possible. These results support the use of efﬁcient respiratory protection in both healthcare
and by the public to limit transmission.
Keywords: SARS-CoV-2; aerosol transmission; viral aerosol; human-generated aerosol
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INTRODUCTION
Since ﬁrst being reported in December of 2019, Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) the etiologic
agent of coronavirus disease 2019 (COVID-19), has rapidly
spread across the globe. Implementing optimal infection
prevention and control (IPC) practices to mitigate disease
spread depends upon a robust understanding of the mechanisms of transmission and relative risk of environmental and
personal exposures. SARS-CoV-2 was originally considered to
spread primarily by droplet and direct contact [1–3]. Similar to
other respiratory viruses, including the closely related severe
acute respiratory syndrome (SARS-CoV-1) and Middle East
respiratory syndrome, the virus can also be transmitted by
aerosolized particles [4], mounting evidence supporting the
importance of airborne transmission [5–8] has resulted in
changes in CDC guidance afﬁrming the importance of aerosol
transmission of COVID-19 [9].

In order to classify an infectious disease as airborne, studies
must show transmission via aerosol particles. The diameter of
particles involved in airborne transmission has been actively
debated over the course of the pandemic. Initially, historical
guidance utilizing a 5 µm cut-off for airborne transmission was
used, but recent work [10, 11], argues that the scientiﬁc basis for
such a cut-off is non-existent, and that a broader range of aerosol
size should be considered to be involved in airborne transmission
of disease. Therefore, there are several lines of evidence that must
be demonstrated in order to establish airborne transmission:
infectious aerosol that is small enough to be transported to and
inhaled by another person must be produced by ill individuals; the
infectious aerosol must be stable long enough to expose another
person; and if inhaled, the viral aerosol must be capable of causing
infection. Experimentally, viral growth in medium from
expired aerosol particles <5 µm has been detected from inﬂuenza
infected humans [12, 13] and several studies have also
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demonstrated culture of SARS-CoV-2 aerosol collected near
infected indivuals [14, 15], thus demonstrating the infectious
nature of the expired particles. SARS-CoV-2 generated aerosols
have been shown to retain infectivity for several hours in the
absence of sunlight [16, 17], and extensive contamination of
COVID-19 patient care areas with SARS-CoV-2 genomic RNA
suggest that aerosol dissemination of virus may occur [18–20]. In
addition, recent clusters of COVID-19 cases linked to a church
choir practice in Washington, U.S.A. and a restaurant
in Guangzhou, China are suggestive of airborne transmission
[21, 22]. Finally, the primary receptor of SARS-CoV-2 for infection is
understood to be ACE2 [23], which is expressed throughout the
human respiratory tract, indicating that inhalation would be a
compatible route of infection.
In April 1, 2020, letter to the White House Ofﬁce of Science and
Technology Policy, the National Academy of Medicine Standing
Committee on Emerging Infectious Diseases, and 21st Century
Health Threats recommended further research into the role of
infectious aerosols in the spread of SARS-CoV-2 [24]. The work
presented here demonstrates that aerosols containing SARS-CoV-2
RNA exist in particle modes that are produced during respiration,
vocalization, and coughing; and that RNA-containing aerosols
<5 µm in diameter contain infectious SARS-CoV-2 virions. The
infectious nature of aerosol collected in this study, taken with
the other lines of evidence presented, illustrates that airborne
transmission of COVID-19 is possible, and that infectious aerosol
may be produced without coughing.
METHODS
Sample collection
Aerosol sampling was conducted around six patients in ﬁve rooms in two
wards (referred to as Ward 5 and Ward 7) on three separate days in April of
2020 (Table S1). Ward 7 was operated with individual rooms at negative
pressure to the hallway, while rooms in Ward 5 could not be individually
isolated. In the case of Ward 5, the entire ward was put into negative
airﬂow with the rest of the ﬂoor. In Ward 7, ventilation, heating and cooling
are controlled centrally. In Ward 5, each rooms has central ventilation and
there is a local fan coil unit in each room for heating and cooling. Room
surfaces were disinfected daily. An Aerodynamic Particle Sizer Spectrometer (APS 3321; TSI, Inc., Shoreview, MN) was used to measure aerosol
concentrations and size distributions from 0.5 µm up to 20 µm. A NIOSH
BC251 sampler [25, 26] was used to collect size-segregated aerosol
samples for both rRT-PCR and culture analysis. The BC251 is a dry air
sampler that when operated at 3.5 Lpm provides three stages of sizesegregated aerosol, >4.1 µm particles collected onto a 15 mL conical tube,
1–4 µm collected onto a 1.5 mL conical tube, and a 37 mm ﬁlter that
collects particles <1 µm. In these studies, a gelatin ﬁlter (Sartorius, GmbH)
was used in the ﬁnal stage for preservation of viral integrity [27]. During
these studies, APS measurements were taken at 1 min intervals for 30 min
in each room, with the exception of Room 5C where loss of battery power
to the laptop collecting the data aborted sampling after 10 min. A single
BC251 sampler was run concurrently, and collocated, with the APS for
30 min in each room at the foot of each patient’s bed with both inlets at
the same height, ~1.1 m from the ﬂoor. A blank 37 mm gelatin ﬁlter was
used as a control for each day to monitor for any cross-contamination of
samples during handling and processing.

Sample recovery, RNA extraction and real-time reverse
transcriptase PCR
Recovery of the samples collected using the BC251 aerosol sampler was
performed by addition of 5 mL of sterile phosphate buffered saline (PBS) to
the 15 mL conical tube, 1 mL of sterile PBS to the 1.5 mL conical tube, and
by placing the 37 mm gelatin ﬁlter from the last stage in a 50 mL conical
tube and dissolving into 10 mL of sterile PBS. Samples were recovered
within 1–2 h of collection. RNA was isolated from recovered samples
immediately after processing.
To recover viral RNA, 400 uL of each recovered sample was processed
using a Qiagen DSP Virus Spin Kit (QIAGEN GMbH, Hilden, Germany). A
negative extraction control (no sample added) was included with each set
of extractions. Samples were eluted in 50 uL of Qiagen AVE Buffer. rRT-PCR

was performed using Invitrogen Superscript III Platinum One-Step
Quantitative rRT-PCR System. Each rRT-PCR run included a positive
synthetic DNA control and a negative, no template, control of nuclease
free water. Reactions were set up and run with initial conditions of 10 min
at 55 °C and 4 min at 94 °C then 45 cycles of 94 °C for 15 s and 58 °C for 30
s, on a QuantStudio™ 3 (Applied Biosytems™, Inc) with the reaction mix and
primers and probe targeting the E gene of SARS-CoV-2 [20, 28] (details
provided in Table S2). Each sample was run in triplicate.
To quantify the virus present in each sample from the measured Ct
values obtained from the rRT-PCR, a standard curve was developed using
RNA extracted from a known quantity of SARS-CoV-2 virus (BEI_ USA-WA1/
2020) cultivated in Vero E6 cells (using the same method described below
for environmental samples). A ﬁve-log standard curve was run in triplicate
beginning at a concentration of 1 × 102 pfu/mL, as determined by plaque
assay. The data were ﬁt with the exponential function:
! "
pfu
¼ 6:0E9 " e#0:707"Ct
(1)
Equivalent Viral Titer
mL
In the equation, Ct is the cycle time where ampliﬁcation is deﬁnitively
above the background. The same cycle threshold was used for all rRT-PCR
runs in this study. Equation 1 was used to convert measured Ct values to an
equivalent viral titer (e-pfu) for each sample. This calibration with extracted
viral RNA more accurately represents the RNA that can be recovered from
virus through the extraction and reverse-transcriptase processes, which are
not accurately captured using a synthetic DNA control. However, e-pfu
may not accurately represent the number of copies associated with a virion
in an environmental sample, as compared to one grown in cell culture.
Therefore, the number of RNA copies/mL as a function of viral titer (pfu/
mL) was determined for this culture. A synthetic DNA control for the SARSCoV-2 E gene (Integrated DNA Technologies, Iowa, USA) that had an initial
concentration of 2 × 108 copies/mL was diluted and assayed via qPCR
using identical assay conditions as RNA extracted from the viral culture
(see above). The number of copies per pfu from cell culture was compared
over ﬁve orders of magnitude in concentration, with Ct values from 23 to
38, and the average was calculated to be 1.35 × 106 ± 6.29 × 105 RNA
copies/pfu. This was then used to determine the RNA copies/L of air in
collected samples.

Cell culture and detection of viral replication
Vero E6 cells were used to culture SARS-CoV-2 virus from environmental
samples within 1–3 days following collection. The cells were cultured in
Dulbeccos’s minimal essential medium (DMEM) supplemented with heat
inactivated fetal bovine serum (10%), penicillin/streptomycin (10,000 IU/mL
& 10,000 µg/mL) and amphotericin B (25 µg/mL). For propagation of
infectious virus from the aerosol samples, 100 µL of undiluted samples, and
a mock infection of 100 µL of SARS-CoV-2 RNA extracted from a culture at
1 × 102 TCID50/mL, were added to 24-well plates containing conﬂuent
monolayers of Vero E6 cells and 3 mL of supplemented DMEM (described
above) and grown at 37̊ °C with 5% CO2. In addition, three additional
infection control experiments were performed using laboratory stock of
SARS-CoV-2. In these experiments, the supplemented DMEM was
inoculated with stock virus to reach supernatant concentrations of 1.6,
1.6 × 10–1, and 1.6 × 10−2 pfu/mL. To look for evidence of viral replication,
RNA was extracted from 140 uL of supernatant from days 1 and either day
5 or 6 of incubation, using the QIAamp Viral RNA Mini Kit (QIAGEN GMbH,
Hilden, Germany) and rRT-PCR was performed on these samples following
the methods described for environmental samples. The percent increase
from day 1 to day 5 or 6 was calculated for all samples to look for evidence
of viral replication in each sample. Deﬁnitive replication was considered to
occur for rRT-PCR samples in which a signiﬁcant increase in RNA was
detected in the supernatant (student’s t test, Microsoft Excel, P < 0.05).
After 6 days, all cell supernatants and lysates were harvested. For samples
with statistically signiﬁcant evidence of replication, subsequent examination of the samples was performed by electron microscopy and western
blot assay. Western blots were generated by harvesting cell lysates in RIPA
lysis buffer. Twenty microliters of lysate was combined with a 2× reducing
sample buffer (Invitrogen), boiled and subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis analysis followed by Western blot using
the antibody against SARS-CoV N protein and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) (Abcam). The gel was examined for protein bands
between 40 and 55 kDa, consistent with the size of the SARS-CoV-2 N
protein. For electron microscopy, samples were ﬁxed, processed,
sectioned, and inspected (see Table S3) on a Tecnai G2 Spirit TWIN
(Thermo Fisher Scientiﬁc) at 80 kV.
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Aerodynamic data analysis
APS measurements were taken at 1 min intervals and exported as mass
concentration in dM/dlogDp per size bin, assuming particles of unit density.
The ﬁrst bin of the APS data ﬁles (<0.523 μm) was discarded during data
analysis. An average concentration across all bins for all 1 min measurements was calculated. The averaged raw distributions were then
parameterized into two log-normally distributed aerosol modes. The
parameterized distributions were assumed to be lognormal and the Solver
function in Microsoft Excel was used to calculate the ﬁt parameters, M, the
total mass concentration, dpg, the mass median aerodynamic diameter, and
σg the geometric standard deviation for each mode by using a
minimization of the sum of least square errors between the raw
distribution and parameterized distributions [29]. The total mass of each
mode contributing to the raw distributions was summed from 0.542 to
0.97 μm, 1.04 to 3.79 μm, and 4.07 to 9.85 μm to reﬂect the size ranges
overlapping with the different stages of BC251 aerosol sampler. The total
concentration in each size bin was normalized such that both the APS
parameterized modes and modes obtained from the rRT-PCR analysis
performed off the BC251 samples could be compared directly.

RESULTS
In all six rooms, rRT-PCR indicated the presence of viral RNA in all
three stages of the BC251 sampler (Fig. 1; Table S4). Furthermore,
exposure of recovered samples to Vero E6 cells demonstrated
statistically signiﬁcant viral growth (95% conﬁdence based on P <
0.05) after 6 days (5 days in the case of the submicron sample
from room 5A) in 3 of the 18 samples (7B, 5A and 5C; Fig. 1). Two
of the 1–4 µm samples demonstrated viral growth, between 90
and 95% conﬁdence (7B and 5C; Fig. 1). A single sample had
deﬁnitive loss of viral RNA during cell culture (5B > 4.1 µm; Fig. 1),
as demonstrated by a growth ratio of <1. The mock infection of
extracted RNA was undetectable by rRT-PCR after 1 day in cell
culture, indicating that ampliﬁcation observed in cultured aerosol
samples was not likely to be from free RNA. The cultures
inoculated with known virus showed statistically signiﬁcant
replication at 10−1 pfu/mL (shown in Fig. 1) and 100 pfu/mL
(shown in Table S4), and no replication at the lowest concentration (10−2).

Cells from the ﬁve environmental samples, where replication
was indicated at >90% conﬁdence by rRT-PCR, were subsequently
examined via western blot, for the presence of viral protein
production, and transmission electron microscopy (TEM) for the
presence of intact SARS-CoV-2 virions. The presence of SARS-CoV2 was observed via western blot for all but one of these samples
(<1 μm, Room 7B; Fig. 2). Images of control gels (Fig. S1) indicate
similar protein bands when infections are started with titers of at
least 10−1. Intact virus was observed via TEM in the submicron
sample from Room 5C (Fig. 3), although it cannot be determined if
these virions were produced during cell culture.
The aerosol size distributions measured in the rooms from ward
5 are all similar, while the rooms in 7 have much lower
concentrations and broader size distributions than those in ward
5 (Fig. S2). The similarities between rooms in each ward, and the
differences between the two wards are likely due in large part to
the background aerosol, rather than differences in aerosol
produced by the patients. The measured distributions were
parameterized, using a log-normal ﬁt and compared with RNA
concentrations measured in the BC251, in an attempt to identify a
human-generated, viral aerosol mode separate from the background. Two log-normal modes were calculated from the
measured APS aerosol mass distributions (Fig. S2 and Table S5).
The mean diameter of the small mode distributions is between
0.64 µm and 0.80 µm for all the rooms sampled (Table S5), while
the width (GSD) of the distribution varied between 1.17 and 1.30.
The large mode distributions had more variability both in terms of
mean diameter and width (Table S5). Unfortunately, a statistically
defensible relationship cannot be made between any of the APS
modes (alone or combined) and RNA extracted from sizesegregated aerosol collected by the BC251 (Table S6). Therefore,
while patient-generated aerosol is a portion of the measured size
distributions, it cannot be separated from the background aerosol
in these rooms. Without a more extensive characterization of
background aerosol in the each of the spaces, it would likely be
impossible to identify the human-generated portion of the aerosol
based solely on size distributions.

Fig. 1 Measured Airborne RNA Concentrations and Associated Percent Change in Viral Copies in Cell Culture. Measured rRT-PCR RNA
copies/L of air (black) indicate in initial viral RNA concentrations while the change viral RNA (red) indicates viral replication in cell culture (or
lack thereof ). Error bars indicate the standard deviation of the RT-PCR-derived concentrations (for air concentration) and calculated
measurement uncertainty (for percent change in cell culture). The P value comparing the RNA in cell culture supernatant on day 1 vs RNA on
the ﬁnal day is shown if the change is positive and the P value is <0.1. Three of the six submicron ﬁlter samples indicated an increase in cell
culture that was signiﬁcant (p < 0.05) based on the Students T Test (7B, 5A and 5C. Two of the 1–4 um samples had P values < 0.1, but not <0.05
(7A and 5C). None of >4.1 um samples demonstrated statistically signiﬁcant replication. Samples with a ratio of <1 indicate a loss of RNA
between the ﬁrst and last day of culture. Cell culture controls (right hand side) indicate the results when known concentration of laboratory
cultured virus are introduced, as well as extracted RNA.
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Fig. 2 Protein expression of SARS-CoV-2. Cell protein lysates were prepared from the indicated cultured samples and subsequently probed
by western blot with a mouse monoclonal anti-SARS nucleocapsid protein (SARS-CoV N) antibody and an anti-GAPDH loading control
antibody. The gel images between 40 and 55 kDa are shown. Images of control gels from infections initiated at titers from 10−2 to 102 pfu/mL
are shown in supplementary Fig. S1, for comparison.

Fig. 3 Electron micrographs of SARS-CoV-2 virions cultivated from the sub-micron ﬁlter from Room 5C. The same image is shown at two
magniﬁcations: (A) ×30,000 and (B) ×110,000. Identiﬁable SARS-CoV-2 virions can be seen at both magniﬁcations, and are indicated by red
arrows in (B).

DISCUSSION
This study sought to characterize the presence of SARS-CoV-2 in
particles consistent with the potential to result in aerosol
transmission between patients. Although the aerosol generated
by the patient cannot be separated from the background using

the size distributions alone, the SARS-CoV-2 RNA extracted from
the BC251 stages provides information about which human
respiratory activities are responsible for producing those particles.
The aerosol collected in the smallest stage of the BC251 (<1 µm) is
consistent with particles found in the smallest mode of exhaled
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breath measured in previous studies [30–33]. This mode of aerosol
was observed in all manner of human respiration including
breathing, vocalization, and coughing [25] and has been
attributed to particles produced in both the bronchial region
[33], referred to as the bronchiolar ﬂuid ﬁlm burst mechanisms
[31], and in the larynx [33] The human-associated fraction of the
aerosol collected in the 1–4 µm stage of the BC251 are also
consistent with production in both the bronchial and laryngeal
regions [33], that are produced in greater numbers during
vocalization and coughing. The aerosol collected in the largest
size bin of the BC251 (>4.1 µm) is almost exclusively composed of
those particles in the largest parameterized size mode and likely
other particles and droplets not measured by the APS. The
human-generated fraction of these larger particles may come
dominantly from the oral cavity and laryngeal region with limited
to no contribution from the bronchial region [33]. Although viral
RNA was consistently observed in aerosol in this largest stage, no
evidence of replicating virus was observed in those samples. This
ﬁnding is consistent with other recent observations by Lednicky
[15]. The differences in potential sources of these particles may
indicate that particles generated deeper in the respiratory tract are
more likely to be culturable.
Observation of ﬁne mode aerosol particles containing infectious
SARS-CoV-2 particles leads to several general observations about
the potential transmission of SARS-CoV-2. The results of this study,
along with the evidence of the stability of SARS-CoV-2 in aerosol
[16, 17] and that SARS-CoV-2 infects respiratory tissue [23] provide
indications that SARS-CoV-2 may be transmitted via the airborne
route. Furthermore, ﬁne mode aerosols are generally produced in
the bronchi and the larynx across a wide range of respiratory
activities, which is in agreement with previous studies in which
SARS-CoV-2 aerosol are observed in the absence of coughing and
other symptoms [20] as well as in reports of disease transmission
by asymptomatic individuals [21, 22].
The most conﬁdent evidence of SARS-CoV-2 replication was
detected in the submicron aerosol collected in the last stage of
the BC251 sampler. This sampler was not originally intended to
collect and preserve the integrity of SARS-CoV-2 in aerosol, and
there have not yet been studies to determine how effective this
approach might be at preserving the infectivity of the virus. In the
ﬁrst two stages of the sampler, the virus is sampled into two dry
conical tubes using inertial impaction. It is possible that this
collection mechanism may be degrading the integrity of the virus
collected in the 1–4 µm and the >4.1 µm stages. For this study, we
employed gelatin ﬁlter in the ﬁnal stage of the BC251 to help
preserve intact virus during collection and notably it was in this
stage that viral replication was observed. However, RatnesarShumate et al. [34] indicate that gelatin ﬁlters and PTFE ﬁlters
perform similarly and similar to the BC251, as a whole, suggesting
that the collection mechanisms used in this study may not have a
signiﬁcant impact on viral stability. These laboratory generated
aerosol have different composition and size than humangenerated particles, so there may be some limitations in the
direct application of these results to the sampling of humangenerated aerosol. Therefore, it can be said that infectious SARSCoV-2 exists in particles <1 µm and may exist in particles up to 4
µm, but it cannot be said that they do not exist in particles larger
than four microns, due to the potential for viral decay during
aerosol collection.
The large number of gene copies per pfu observed in the rRTPCR controls may also offer some insight into the challenges in
isolating this virus from aerosol samples. The high gene copy to
pfu ratio may indicate a large number of defective interfering (DI)
particles exist under culture conditions. Other betacoronaviruses
are known to produce DI particles in culture. [35] In addition, a
similar result has been observed in patient samples. Scola et al.
[36] demonstrated that while high viral loads can be measured in
patients by rRT-PCR, no culture positive samples were found with
Journal of Exposure Science & Environmental Epidemiology

Ct values higher than 34. It is unclear if DI particles are involved in
these instances, but it is clear that large quantities of RNA are
present in both cell culture and human infections even in the
absence of high titers of infectious virions. Therefore, despite the
ubiquitous RNA contamination observed in the patient environment, it seems that the portion of that contamination that
represents infectious virus may be small by comparison. This
needs to be considered when interpreting observations of viral
RNA in these and other aerosol samples.
CONCLUSION
Our results demonstrate that SARS-CoV-2 RNA exists in respired
aerosols <5 µm in diameter; that aerosols containing SARS-CoV-2
RNA exist in particle modes that have been demonstrated to be
produced during respiration, vocalization, and coughing [33]; and
that some fraction of the RNA-containing aerosols contain intact,
replication-competent virions (Table S7).
This study supports the role ﬁne mode aerosols in the
transmission of SARS-CoV-2, and emphasizes the importance of
efﬁcient respiratory protection and airborne isolation precautions
to protect from exposure to ﬁne SARS-CoV-2 aerosol when
interacting with infected individuals, regardless of symptoms or
medical procedure being performed.
Given the ongoing circulation of COVID-19, and recent work
highlighting the relative importance of airborne transmission of
COVID-19 [5], it is crucial that evidenced-based IPC practices are
promoted and implemented to limit the transmission of SARSCoV-2 in healthcare, and that efﬁcient respiratory protection and
hygiene practices are used in public and industry settings. The
results of this study, taken with the other lines of evidence
presented, further suggests that airborne transmission of COVID19 is likely in many situations, and that aerosol prevention
measures should be implemented to effectively stem the spread
of SARS-CoV-2, particularly in crowded settings.

DATA AVAILABILITY
All data are available in the main text or the supplementary materials.
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